AbbVie Inc. P/E ratio

P/E ratio of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/E ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its earnings per share. A low P/E ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/E ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Current P/E ratio of AbbVie Inc. is 16.77 (as of December 30, 2019)
  • P/E ratio for the quarter ending December 30, 2019 was 16.77 (a -51.94% decrease compared to previous quarter)
  • Year-over-year quarterly P/E ratio decreased by -27.55%
  • Annual P/E ratio for 2019 was 16.77 (a -34.88% decrease from previous year)
  • Annual P/E ratio for 2018 was 25.75 (a -13.91% decrease from previous year)
  • Annual P/E ratio for 2017 was 29.91 (a 73.98% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/E ratio of AbbVie Inc.

Most recent P/E ratioof ABBV including historical data for past 10 years.

Interactive Chart of P/E ratio of AbbVie Inc.

AbbVie Inc. P/E ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 16.77 34.89 26.99 23.15 16.77
2018 25.75 19.63 23.05 23.04 25.75
2017 29.91 21.99 17.82 16.88 29.91
2016 17.19 17.05 17.84 17.2 17.19
2015 18.99 32.2 53.33 52.74 18.99
2014 60.04 25.11 21.79 20.0 60.04
2013 20.63 15.75 12.8 12.13 20.63
2012 10.48 10.48 10.48 10.48 10.48
2011 10.48 10.48 10.48 10.48 10.48
2010 10.48
2009 10.48

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.